Skip to main content
OpenTrials
Completed

NCT Number: NCT00000239

Buprenorphine Pharmacology Related to Addiction Treatment - 21

The purpose of this study is to examine if chronic buprenorphine administration will generate supersensitivity to opiates.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Opioid-related Disorders Chemically-Induced Disorders Mental Disorders Narcotic-Related Disorders Substance-Related Disorders

Age range

0 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Treatment Research Center

Burlington, Vermont, 05401, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

buprenorphine

Drug

Primary outcomes

  1. Drug use

  2. Opioid agonist effects

  3. Opiate withdrawal

  4. Physiological changes in: pupil diameter, blood pressure, heart rate, respiration

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

  • University of Vermont

Registry information

Official study title

Buprenorphine Pharmacology Related to Addiction Treatment

Important dates

First posted
Sep 21, 1999
Registry last updated
Aug 17, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.